Shai Schubert is a biotechnology entrepreneur and co-founder and CEO of Feromics, a Boston-based functional immunomics platform company working at the intersection of biology and machine learning. At Feromics, Dr. Schubert leads the development of the Intelligent Design™ platform — a function-first discovery workflow that physically isolates immune cells based on directly observed behavior before any molecular data is collected. This produces training-grade data with verified functional labels built in at the biological source level, enabling AI models that train faster, require fewer samples, and generate discoveries that translate. The platform has been independently validated by the U.S. government through a $4.1 million contract from ARPA-H, the Advanced Research Projects Agency for Health. Prior to co-founding Feromics, Dr. Schubert co-founded and led technology development across multiple biotechnology and medical device companies. He holds a PhD in Biotechnology from the Technion – Israel Institute of Technology and completed his postdoctoral training at the Harvard-MIT Program in Health Sciences and Technology, Biomedical Engineering Center.

Tania Konry is a bioengineer, scientist, and co-founder of Feromics, a Boston-based functional immunomics platform company working at the intersection of biology and machine learning.   Dr. Konry established the foundational research that became Feromics at her laboratory at Northeastern University, where engineers, biologists, and computer scientists developed a novel biotechnology for single-cell assays in cancer and autoimmune disease. Since 2013, this work has produced over 52 scientific papers and patents, alongside collaborations with leading pharmaceutical companies — and forms the scientific core of the Intelligent Design™ platform. The platform has been independently validated by the U.S. government through a $4.1 million contract from ARPA-H, the Advanced Research Projects Agency for Health.   Dr. Konry is an Associate Professor in the Department of Pharmaceutical Sciences at the Bouvé College of Health Sciences, and serves as Assistant Dean for Research at the School of Pharmacy and Pharmaceutical Sciences at Northeastern University. She holds a PhD in Biotechnology and received advanced training in bioengineering at the Center for Engineering in Medicine at Massachusetts General Hospital, Harvard Medical School. Prior to founding Feromics